Quick Answer
Abivax S.A. reported Total Assets of $584.34 million for fiscal year 2025.
Abivax S.A. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $584.34M +184.7% |
$205.23M -37.3% |
$327.06M +332.9% |
$75.54M -30.8% |
$109.23M |
| R&D Expense | $177.76M +21.3% |
$146.53M +42.0% |
$103.18M +113.6% |
$48.30M +1.1% |
$47.78M |
- Abivax S.A. reported Total Assets of $584.34 million for fiscal year 2025.
- Abivax S.A. showed an increase of +184.7% in Total Assets compared to the prior fiscal year.
- Abivax S.A. reported R&D Expense of $177.76 million for fiscal year 2025.
- Abivax S.A. showed an increase of +21.3% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: